Artivion(AORT)

Search documents
Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting
Prnewswire· 2024-04-29 12:05
5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study Late-Breaking 30-Day Data from AMDS PERSEVERE Trial Demonstrate Positive Aortic Remodeling Outcomes and Zero DANE Tears ATLANTA, April 29, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from the On-X Low ...
Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Prnewswire· 2024-04-01 20:10
ATLANTA, April 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 23rd Annual Needham Virtual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 10:15 a.m. ET on Monday, April 8, 2024. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of ...
Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?
Zacks Investment Research· 2024-03-29 14:16
Have you been paying attention to shares of Artivion (AORT) ? Shares have been on the move with the stock up 9.6% over the past month. The stock hit a new 52-week high of $21.82 in the previous session. Artivion has gained 18.3% since the start of the year compared to the 8.2% move for the Zacks Medical sector and the 9.4% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings c ...
3 Buy-Rated Small Caps Flexing Big Growth
Zacks Investment Research· 2024-03-19 21:31
As many know, small-caps’ volatile nature can sometimes turn investors away.However, many small-cap stocks turn out to be big winners in the long run, and they typically have fewer eyes on them, providing investors an opportunity to get in "early" before the crowd.For those seeking exposure to small-caps, three stocks – EZCORP (EZPW) , Artivion (AORT) , and QuickLogic (QUIK) – could all be considered.All three sport a favorable Zacks Rank, indicating optimism among analysts. Let’s take a closer look at each ...
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
Zacks Investment Research· 2024-03-14 14:51
The Medical Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. The industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to its original space of point-of-care testing, heavy as well as minimally invasive implants, elective procedures, and so on and so forth.The medical instruments space has been benefiting from the ongoing merger and acquisition trend. The smaller and mi ...
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research· 2024-03-12 14:46
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Artivion (AORT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Artivion is a member of our Medical group, which includes 1066 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges th ...
Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Prnewswire· 2024-03-06 21:10
ATLANTA, March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 13, 2023. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived ...
Artivion(AORT) - 2023 Q4 - Annual Report
2024-02-22 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 59-2417093 (State or other jurisdiction of incorpo ...
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
Zacks Investment Research· 2024-02-22 15:45
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Artivion (AORT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Artivion is one of 1067 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Ran ...
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
Zacks Investment Research· 2024-02-22 15:15
Shares of Artivion (AORT) have been strong performers lately, with the stock up 15.9% over the past month. The stock hit a new 52-week high of $19.63 in the previous session. Artivion has gained 9.5% since the start of the year compared to the 6% move for the Zacks Medical sector and the 4.4% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last ...